← Back to Search

The Residential Care Transition Module for Alzheimer's Disease (RCTM Trial)

N/A
Waitlist Available
Led By Joseph E. Gaugler, PhD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0, 1 and 4 months post-pandemic onset
Awards & highlights

RCTM Trial Summary

This study is evaluating whether a psychosocial intervention can help families better navigate the residential care transitions of relatives with Alzheimer's disease or a related dementia.

Eligible Conditions
  • Alzheimer's Disease
  • Dementia

RCTM Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0, 1 and 4 months post-pandemic onset
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0, 1 and 4 months post-pandemic onset for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in burden: Zarit Burden Interview
Change in care-related strain
Change in stress: Perceived Stress Scale
Secondary outcome measures
Qualitative measure of resilience to negative psychosocial effects of COVID-19
Quantitative measure of resilience to negative psychosocial effects of COVID-19

RCTM Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Treatment GroupExperimental Treatment1 Intervention
The Residential Care Transition Module (RCTM) includes six in-person consultation sessions over a 4-month period conducted by a trained Transition Counselor (TC) with a primary family caregiver (self-identified as the person most responsible for providing on-going assistance to the care recipient in a residential long-term care setting such (RLTC) such as a nursing home or assisted living memory care unit.
Group II: Usual Care GroupActive Control1 Intervention
The usual care control group will adjust for the social engagement provided to the Residential Care Transition Module (RCTM )treatment condition. The Transition Counselor (TC) will provide quarterly contact calls and the research coordinator will send a bi-annual project newsletter to all participants. If caregivers in the control group initiate contact with the TC for care needs, the TC will provide information and referral support.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
The Residential Care Transition Module
2016
N/A
~240

Find a Location

Who is running the clinical trial?

NYU Langone HealthOTHER
1,368 Previous Clinical Trials
839,486 Total Patients Enrolled
Johns Hopkins UniversityOTHER
2,263 Previous Clinical Trials
14,822,925 Total Patients Enrolled
Benjamin Rose InstituteOTHER
1 Previous Clinical Trials
994 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
The Residential Care Transition Module
2016. "The Residential Care Transition Module". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02915939.
~29 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top